JP7290627B2 - Ａｔｒキナーゼの複素環式阻害剤 - Google Patents

Ａｔｒキナーゼの複素環式阻害剤 Download PDF

Info

Publication number
JP7290627B2
JP7290627B2 JP2020508534A JP2020508534A JP7290627B2 JP 7290627 B2 JP7290627 B2 JP 7290627B2 JP 2020508534 A JP2020508534 A JP 2020508534A JP 2020508534 A JP2020508534 A JP 2020508534A JP 7290627 B2 JP7290627 B2 JP 7290627B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkoxy
membered heterocycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531447A5 (enExample
JP2020531447A (ja
Inventor
エミリア ディ フランチェスコ マリア
ジョーンズ フィリップ
ローレンス キャロル クリストファー
ブライアント クロス ジェーソン
カン ジジュン
ギャレット ジョンソン マイケル
ライブリー サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chempartner Corp
University of Texas System
Original Assignee
Chempartner Corp
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chempartner Corp, University of Texas System filed Critical Chempartner Corp
Publication of JP2020531447A publication Critical patent/JP2020531447A/ja
Publication of JP2020531447A5 publication Critical patent/JP2020531447A5/ja
Application granted granted Critical
Publication of JP7290627B2 publication Critical patent/JP7290627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020508534A 2017-08-17 2018-08-17 Ａｔｒキナーゼの複素環式阻害剤 Active JP7290627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546944P 2017-08-17 2017-08-17
US62/546,944 2017-08-17
PCT/US2018/046937 WO2019036641A1 (en) 2017-08-17 2018-08-17 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (3)

Publication Number Publication Date
JP2020531447A JP2020531447A (ja) 2020-11-05
JP2020531447A5 JP2020531447A5 (enExample) 2021-09-24
JP7290627B2 true JP7290627B2 (ja) 2023-06-13

Family

ID=65361058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508534A Active JP7290627B2 (ja) 2017-08-17 2018-08-17 Ａｔｒキナーゼの複素環式阻害剤

Country Status (5)

Country Link
US (1) US10800774B2 (enExample)
EP (1) EP3668839B1 (enExample)
JP (1) JP7290627B2 (enExample)
CN (1) CN111886224B (enExample)
WO (1) WO2019036641A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
CN111867590B (zh) 2017-07-13 2023-11-17 德州大学系统董事会 Atr激酶的杂环抑制剂
CN111886224B (zh) 2017-08-17 2024-07-23 德州大学系统董事会 Atr激酶的杂环抑制剂
JP7235338B2 (ja) * 2017-09-08 2023-03-08 ニューウェーブ・ファーマスーティカル・インコーポレイテッド Ａｔｒ阻害剤としての置換ピロロピリジン
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
JP2022510501A (ja) 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
EP4011881B1 (en) 2019-08-06 2025-02-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystalline forms of an atr inhibitor and use thereof
US12448378B2 (en) 2020-05-29 2025-10-21 Wuxi Life Fountain Biotech Co., Ltd Fluoropyrrolopyridine compound and application thereof
ES3054165T3 (en) * 2020-10-16 2026-01-30 Shanghai De Novo Pharmatech Co Ltd Triheterocyclic derivative, and pharmaceutical composition and application thereof
CN116178366B (zh) * 2021-11-26 2025-03-18 无锡瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527464A (ja) 2006-01-20 2009-07-30 ノバルティス アクチエンゲゼルシャフト Ｐｉ−３キナーゼ阻害剤として使用されるピリミジン誘導体
JP2010503650A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のための、ｐｉ３ｋおよびｍｔｏｒ阻害剤としての２−ベンズイミダゾリル−６−モルホリノ−４−ピペリジン−４−イルピリミジン誘導体
JP2012513388A (ja) 2008-12-22 2012-06-14 アストラゼネカ アクチボラグ 癌を処置するためのピリミジンインドール誘導体
JP2012521983A (ja) 2009-03-27 2012-09-20 パトフワイ トヘラペウトイクス インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
JP2013528204A (ja) 2010-06-11 2013-07-08 アストラゼネカ アクチボラグ モルホリノピリミジンおよび治療におけるそれらの使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49570B1 (en) 1979-03-30 1985-10-30 Rhone Poulenc Ind 2-(pyrid-2-yl)tetrahydrothiophene derivatives
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
JP5534811B2 (ja) 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
BRPI0810646A2 (pt) 2007-04-12 2014-11-04 Hoffmann La Roche " compostos farmacêuticos ".
US20080292588A1 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
BRPI0814818A2 (pt) 2007-07-09 2019-09-10 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
WO2016061097A1 (en) 2014-10-13 2016-04-21 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
CA3023765A1 (en) 2016-05-24 2017-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors
US10774064B2 (en) * 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
CN111867590B (zh) 2017-07-13 2023-11-17 德州大学系统董事会 Atr激酶的杂环抑制剂
CN111886224B (zh) 2017-08-17 2024-07-23 德州大学系统董事会 Atr激酶的杂环抑制剂
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527464A (ja) 2006-01-20 2009-07-30 ノバルティス アクチエンゲゼルシャフト Ｐｉ−３キナーゼ阻害剤として使用されるピリミジン誘導体
JP2010503650A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のための、ｐｉ３ｋおよびｍｔｏｒ阻害剤としての２−ベンズイミダゾリル−６−モルホリノ−４−ピペリジン−４−イルピリミジン誘導体
JP2012513388A (ja) 2008-12-22 2012-06-14 アストラゼネカ アクチボラグ 癌を処置するためのピリミジンインドール誘導体
JP2012521983A (ja) 2009-03-27 2012-09-20 パトフワイ トヘラペウトイクス インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
JP2013528204A (ja) 2010-06-11 2013-07-08 アストラゼネカ アクチボラグ モルホリノピリミジンおよび治療におけるそれらの使用

Also Published As

Publication number Publication date
WO2019036641A1 (en) 2019-02-21
US20190055240A1 (en) 2019-02-21
EP3668839A4 (en) 2021-03-31
US10800774B2 (en) 2020-10-13
CN111886224B (zh) 2024-07-23
EP3668839A1 (en) 2020-06-24
JP2020531447A (ja) 2020-11-05
CN111886224A (zh) 2020-11-03
EP3668839B1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CN111886224B (zh) Atr激酶的杂环抑制剂
AU2019263294B2 (en) Substituted heterocyclic inhibitors of PTPN11
US11434233B2 (en) Heterocyclic inhibitors of ATR kinase
JP7341156B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
US10745420B2 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
HK40028148A (en) Heterocyclic inhibitors of atr kinase
HK40028148B (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230601

R150 Certificate of patent or registration of utility model

Ref document number: 7290627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150